Robbins LLP is Investigating Allegations that CVRx, Inc. (CVRX) Misled Investors Regarding Misconduct that Exposed the Company to Liability under the False Claims Act and Anti-Kickback Statute

Robbins LLP informs investors that a class action was filed on behalf of all persons who purchased or otherwise acquired CVRx, Inc. (NASDQAQ: CRVX) common stock between July 25, 2023 and August 6, 2026, inclusive (the “Class Period”). CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular disease.

Why Was CVRx Sued?

According to the complaint, during the Class Period, defendants made false and misleading statements regarding the Company’s financial results and business, operations, and compliance policies. Specifically, defendants failed to disclose that:

(a) to induce sales growth, CVRx and/or its employees were engaged in illegal and unsustainable sales practices, including improperly marketing Barostim, offering or paying kickbacks, and providing false information to government health insurance programs in violation of the False Claims Act (“FCA”) and Anti-Kickback Statute (“AKS”);

(b) CVRx’s revenues were in part the product of such unlawful conduct and thus unsustainable;

(c) the illegal sales and marketing activities increased the risk of criminal and civil liability; and

(d) as a result of the foregoing, defendants’ public statements, including the Company’s reported revenue, purported growth drivers, compliance with the FCA and AKS, the effectiveness of its patient access and reimbursement strategy, and the effectiveness of CVRx’s internal controls over financial reporting were materially false and misleading at all relevant times.

In addition, the complaint alleges that defendants made materially false and misleading statements regarding the progress of the Company’s sales force realignment and the transformation of its commercial organization.

Why Did CVRx Stock Drop?

Plaintiff alleges that on August 6, 2026, CVRx disclosed that on May 14, 2026, the Company “received a civil investigative demand (‘CID’) from the U.S. Department of Justice in connection with an investigation under the False Claims Act.” The Company stated that the “CID requested information and documents regarding an investigation into whether [CVRx] caused the submission of false claims to government health insurance programs by improperly marketing [its] device, offering or paying kickbacks to healthcare providers or providing false information to government health insurance programs.”

On the same date, CVRx cut its outlook based, in part, on weak sales force productivity.

On this news, the price of CVRx common stock fell $3.55 per share, or 60%, to close at $2.39 per share on August 7, 2026.

Who May Be Eligible to Participate in the CVRX, Inc. Class Action?

The lawsuit seeks to represent investors who purchased or otherwise acquired CVRX, Inc. common stock between July 25, 2023 and August 6, 2026. Investors who suffered losses during that period may have legal rights under the federal securities laws. Submit a form for information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.